The American Journal of Medicine
Volume 118, Issue 6 , Pages 625-635 , June 2005

Oral anticoagulation strategies after a first idiopathic venous thromboembolic event

  • Drahomir Aujesky, MD, MSc

      Affiliations

    • Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pennsylvania
    • VA Center for Health Equity Research and Promotion and VA Pittsburgh Healthcare System, Pennsylvania
    • Corresponding Author InformationRequests for reprints should be addressed to Drahomir Aujesky, MD, MSc, Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, University Drive C, Building #28, Suite 1A129, Pittsburgh, PA 15240
    • ,
  • Kenneth J. Smith, MD

      Affiliations

    • Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pennsylvania
    • Section of Decision Sciences and Clinical Systems Modeling, Department of Medicine, University of Pittsburgh, Pennsylvania
    • ,
  • Mark S. Roberts, MD, MPP

      Affiliations

    • Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pennsylvania
    • Section of Decision Sciences and Clinical Systems Modeling, Department of Medicine, University of Pittsburgh, Pennsylvania

References 

  1. Prandoni P , Lensing AW , Cogo A , et al.   The long-term clinical course of acute deep venous thrombosis . Ann Intern Med. . 1996;125:1–7
  2. Buller HR , Agnelli G , Hull RD , et al.   Antithrombotic therapy for venous thromboembolic disease (the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy) . Chest . 2004;126:401S–428S
  3. Levine MN , Raskob G , Beyth RJ , et al.   Hemorrhagic complications of anticoagulant treatment (the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy) . Chest . 2004;126:287S–310S
  4. Pinede L , Ninet J , Duhaut P , et al.   Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis . Circulation . 2001;103:2453–2460
  5. Agnelli G , Prandoni P , Santamaria MG , et al.  Warfarin Optimal Duration Italian Trial Investigators   Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis . N Engl J Med. . 2001;345:165–169
  6. Agnelli G , Prandoni P , Becattini C , et al.   Extended oral anticoagulant therapy after a first episode of pulmonary embolism . Ann Intern Med. . 2003;139:19–25
  7. Ridker PM , Goldhaber SZ , Danielson E , et al.   Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism . N Engl J Med. . 2003;348:1425–1434
  8. Kearon C , Ginsberg JS , Kovacs MJ , et al.   Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism . N Engl J Med. . 2003;349:631–639
  9. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism . Thorax . 2003;58:470–483
  10. Kearon C . Long-term management of patients after venous thromboembolism . Circulation . 2004;110:110–118
  11. Van der Meer FJ , Rosendaal FR , Vandenbroucke JP , Briet E . Bleeding complications in oral anticoagulant therapy. An analysis of risk factors . Arch Intern Med. . 1993;153:1557–1562
  12. Van der Meer FJ , Rosendaal FR , Vandenbroucke JP , Briet E . Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants . Thromb Haemost . 1996;76:12–16
  13. Kyrle PA , Minar E , Bialonczyk C , et al.   The risk of recurrent venous thromboembolism in men and women . N Engl J Med. . 2004;350:2558–2563
  14. Schulman S , Wahlander K , Lundstrom T , Clason SB , Eriksson H , Investigators TI . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran . N Engl J Med. . 2003;349:1713–1721
  15. Sonnenberg FA , Beck JR . Markov models in medical decision making (a practical guide) . Med Decis Making . 1993;13:322–338
  16. Weinstein MC , Siegel JE , Gold MR , et al.   Recommendations of the Panel on Cost-effectiveness in Health and Medicine . JAMA . 1996;276:1253–1258
  17. Kearon C , Gent M , Hirsh J , et al.   A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism . N Engl J Med. . 1999;340:901–907
  18. Kearon C . Rate of recurrent venous thromboembolism (VTE) after completing two years of anticoagulation for a first episode of idiopathic VTE . [Abstract] Thromb Haemost. . 2001;7(Suppl.):P794
  19. White RH , McKittrick T , Takakuwa J , et al.  National Consortium of Anticoagulation Clinics   Management and prognosis of life-threatening bleeding during warfarin therapy . Arch Intern Med. . 1996;156:1197–1201
  20. Collins TC , Petersen NJ , Menke TJ , et al.   Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke . J Clin Epidemiol. . 2003;56:81–87
  21. Rosand J , Eckman MH , Knudsen KA , et al.   The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage . Arch Intern Med. . 2004;164:880–884
  22. Decousus H , Leizorovicz A , Parent F , et al.  Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group   A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis . N Engl J Med. . 1998;338:409–415
  23. Arias E . United States life tables, 2000. National vital statistics reports; vol 51, no 3 . Hyattsville, MD: National Center for Health Statistics; 2002;
  24. Lindmarker P , Schulman S , Sten-Linder M , et al.   The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation . Thromb Haemost. . 1999;81:684–689
  25. Cushman M , Tsai AW , White RH , et al.   Deep vein thrombosis and pulmonary embolism in two cohorts (the longitudinal investigation of thromboembolism etiology) . Am J Med. . 2004;117:19–25
  26. Pengo V , Legnani C , Noventa F , Palareti G . Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding (a multicenter inception cohort study) . Thromb Haemost. . 2001;85:418–422
  27. Beck JR , Pauker SG , Gottlieb JE , et al.   A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making . Am J Med. . 1982;73(6):889–897
  28. Gould MK , Dembitzer AD , Sanders GD , Garber AM . Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. a cost-effectiveness analysis . Ann Intern Med. . 1999;130:789–799
  29. Auerbach AD , Sanders GD , Hambleton J . Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis . Am J Med. . 2004;116:816–828
  30. From the Medicare Provider Analysis and Review (MEDPAR) of Short-Stay Hospitals Web site. Available at: http://cms.hhs.gov/statistics/medpar/default.asp. Accessed September 30, 2004.
  31. Gold MR , Franks P , McCoy KI , Fryback DG . Toward consistency in cost-utility analyses (using national measures to create condition-specific values) . Med Care . 1998;36:778–792
  32. Drug Topics Red Book . Montvale, NY: Medical Economics; 2002;
  33. From the Centers for Medicare & Medicaid Services web site. Available at: http://cms.hhs.gov/providers/pufdownload/default.asp. Accessed September 30, 2004.
  34. From the U.S. Bureau of Labor Statistics Web site. Available at: http://www.bls.gov/data/. Accessed September 30, 2004.
  35. Hirth RA , Chernew ME , Miller E , et al.   Willingness to pay for a quality-adjusted life year (in search of a standard) . Med Decis Making . 2000;20(3):332–342
  36. Doubilet P , Begg CB , Weinstein MC , et al.   Probabilistic sensitivity analysis using Monte Carlo simulation (a practical approach) . Med Decis Making . 1985;5:157–177
  37. Stinnett AA , Mullahy J . Net health benefits (a new framework for the analysis of uncertainty in cost-effectiveness analysis) . Med Decis Making . 1998;18:S68–S80
  38. Van Dongen CJ , Vink R , Hutten BA , et al.   The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event (a meta-analysis) . Arch Intern Med. . 2003;163:1285–1293
  39. Frazee LA , Chomo DL . Duration of anticoagulant therapy after initial idiopathic venous thromboembolism . Ann Pharmacother. . 2003;37:1489–1496
  40. Douketis JD , Kearon C , Bates S , et al.   Risk of fatal pulmonary embolism in patients with treated venous thromboembolism . JAMA . 1998;279:458–462
  41. Beyth RJ , Quinn LM , Landefeld CS . Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin . Am J Med. . 1998;105:91–99
  42. Wells PS , Forgie MA , Simms M , et al.   The outpatient bleeding risk index (validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism) . Arch Intern Med. . 2003;163:917–920
  43. Sarasin FP , Bounameaux H . Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis . BMJ . 1998;316(7125):95–99
  44. Eckman MH , Singh SK , Erban JK , Kao G . Testing for factor V Leiden in patients with pulmonary or venous thromboembolism (a cost-effectiveness analysis) . Med Decis Making . 2002;22:108–124
  45. Marchetti M , Pistorio A , Barosi G . Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden—cost-effectiveness analysis . Thromb Haemost. . 2000;84(5):752–757
  46. Van den Belt AG , Hutten BA , Prins MH , Bossuy PM . Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S—a decision analysis . Thromb Haemost. . 2000;84:758–763
  47. Pengo V , Lensing AW , Prins MH , et al.   Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism . N Engl J Med. . 2004;350:2257–2264
  48. Linkins LA , Choi PT , Douketis JD . Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism (a meta-analysis) . Ann Intern Med. . 2003;139:893–900
  49. Luk C , Wells PS , Anderson D , Kovacs MJ . Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy . Am J Med. . 2001;111:270–273
  50. Becker DM , Philbrick JT , Selby JB . Inferior vena cava filters. Indications, safety, effectiveness . Arch Intern Med. . 1992;152:1985–1994
  51. Lenert LA , Soetikno RM . Automated computer interviews to elicit utilities (potential applications in the treatment of deep venous thrombosis) . J Am Med Inform Assoc. . 1997;4:49–56
  52. Gage BF , Cardinalli AB , Albers GW , Owens DK . Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation . JAMA . 1995;274:1839–1845
  53. Marchetti M , Pistorio A , Barone M , et al.   Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism (a cost-effectiveness analysis) . Am J Med. . 2001;111:130–139
  54. Teng J , Mayo NE , Latimer E , et al.   Costs and caregiver consequences of early supported discharge for stroke patients . Stroke . 2003;34:528–536
  55. Caprini JA , Botteman MF , Stephens JM , et al.   Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States . Value Health . 2003;6:59–74

PII: S0002-9343(05)00137-3

doi: 10.1016/j.amjmed.2005.02.018

The American Journal of Medicine
Volume 118, Issue 6 , Pages 625-635 , June 2005

Article Tools